API Brutinib Powder Raw Material Ibrutinib Powder Ibrutinib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Model NO.: D-sung Ibrutinib
• Model No.: D-Sung Ibrutinib
• Product Name: Ibrutinib
• Name: Ibrutinib Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Anticancer
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 936563-96-1
• Mf: C25h24n6o2
• MW: 440.507
• Melting Point: 149-158oc
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• Production Capacity: 500kg/Month

Product Description

 

Product Description

API brutinib powder Raw Material Ibrutinib powder Ibrutinib
 

Product Description

Product Details

Product name	Ibrutinib
Cas number	936563-96-1
Apperance	White powder
MF	C25H24N6O2
MW	440.507

Ibrutinib, a targeted anticarcinogenesis drug developed by Johnson Johnson and Pharmacyclics Inc., was approved by the U.S. Food and Drug Administration (FDA) on November 13, 2013.The drug, marketed under the trade name Imbruvica, is used for the treatment of mantle cell lymphoma (MCL).

Application&Function

Ibrutinib is a highly selective Bruton's tyrosine kinase (Btk) irreversible inhibitor.PCI-32765 (Ibrutinib) is a selective and irreversible pyrrolopyrimidine-based inhibitor of BTK with IC50 of 0.5 nM. [1] PCI-32765 binds irreversibly to Cys-481 in BTK and thus is only active with other kinases with such a modifiable cysteine residue. In DOHH2 cells, in which the BCR pathway can be activated by anti-IgG, PCI-32765 inhibits autophosphorylation of BTK (IC50, 11 nM), BTK's physiological substrate, PLCg (IC50, 29 nm), and downstream ERK (IC50, 13 nm). 
PCI-32765 (Ibrutinib) may be an important new targeted treatment approach for CLL pts. In ex vivo assays with whole bold, PCI-32765 (Ibrutinib) prevents the activation of human BCR with an IC50 of about 0.2 μM, while not influencing the activation of T cell. Treatment of CD40 or BCR activated CLL cells with PCI-32765 (Ibrutinib) results in inhibition of BTK tyrosine phosphorylation and also effectively abrogates downstream survival pathways activated by this kinase including ERK1/2, PI3K, and NF-κB. In addition, PCI-32765 (Ibrutinib) prevents activation-induced proliferation of CLL cells in vitro, and effectively inhibits survival signals provided externally to CLL cells from the microenvironment including soluble factors (CD40L, BAFF, IL-6, IL-4, and TNF-α), fibronectin engagement, and stromal cell contact. PCI-32765 is originally developed by Pharmacyclics. And participants is been invited for the phase I clinical trials.

Specification